4BASEBIO PLC EO 1
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5' and 3' ends for viral and non-viral vector applicat… Read more
4BASEBIO PLC EO 1 (88Q) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, 4BASEBIO PLC EO 1 (88Q) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
4BASEBIO PLC EO 1 - Net Assets Trend (None–None)
This chart illustrates how 4BASEBIO PLC EO 1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 4BASEBIO PLC EO 1 (None–None)
The table below shows the annual net assets of 4BASEBIO PLC EO 1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to 4BASEBIO PLC EO 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
4BASEBIO PLC EO 1 Competitors by Market Cap
The table below lists competitors of 4BASEBIO PLC EO 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Taiwan Pelican Express Co Ltd
TW:2642
|
$32.17 Million |
|
PT Mandiri Herindo Adiperkasa Tbk
JK:MAHA
|
$32.18 Million |
|
Aksu Enerji ve Ticaret AS
IS:AKSUE
|
$32.18 Million |
|
Schoolblazer Limited
AU:SBZ
|
$32.19 Million |
|
FIH Mobile Limited
PINK:FXCNF
|
$32.17 Million |
|
Bragg Gaming Group Inc
NASDAQ:BRAG
|
$32.17 Million |
|
SaverOne 2014 Ltd. Warrant
NASDAQ:SVREW
|
$32.17 Million |
|
Champions Oncology Inc
NASDAQ:CSBR
|
$32.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 4BASEBIO PLC EO 1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares 4BASEBIO PLC EO 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently 4BASEBIO PLC EO 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares 4BASEBIO PLC EO 1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 4BASEBIO PLC EO 1 (88Q) | €- | N/A | N/A | $32.17 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |